Journal of Hepatocellular Carcinoma
Volume 10, 2023 - Issue
ORIGINAL RESEARCH
Early Tumor Marker Response Predicts Treatment Outcomes in Patients with Unresectable Hepatocellular Carcinoma Receiving Combined Lenvatinib, Immune Checkpoint Inhibitors, and Transcatheter Arterial Chemoembolization Therapy
Meng-Chao Luo1 Shengli Clinical Medical College of Fujian Medical University, Fuzhou, Fujian Province, 350001, People’s Republic of China;2 Department of General Surgery, Fujian Provincial Hospital, Fuzhou, Fujian Province, 350001, People’s Republic of China
https://orcid.org/0009-0009-8041-3086View further author information
https://orcid.org/0009-0009-8041-3086View further author information, Jia-Yi Wu1 Shengli Clinical Medical College of Fujian Medical University, Fuzhou, Fujian Province, 350001, People’s Republic of China;3 Department of Hepatobiliary Pancreatic Surgery, Fujian Provincial Hospital, Fuzhou, Fujian Province, 350001, People’s Republic of Chinahttps://orcid.org/0000-0001-5371-8989View further author information
https://orcid.org/0000-0001-5371-8989View further author information, , , , Zhen-Xin Zeng3 Department of Hepatobiliary Pancreatic Surgery, Fujian Provincial Hospital, Fuzhou, Fujian Province, 350001, People’s Republic of Chinahttps://orcid.org/0000-0001-5706-8629View further author information
https://orcid.org/0000-0001-5706-8629View further author information, & show all